Jamie I. Fletcher

Cancer Institute of New South Wales — Australia

Medicine · Health Sciences

33h-index9.4kcitations250works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(142), Protein Degradation and Inhibitors(49), Cancer therapeutics and mechanisms(35), Cancer, Hypoxia, and Metabolism(28), Histone Deacetylase Inhibitors Research(19)

Publications250 total

Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma
Science Advances·2025Open Access
Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma
Journal of Medicinal Chemistry·2025Open Access
P-glycoprotein as a chemotherapy resistance mechanism and biomarker of poor response in high-risk neuroblastoma
EJC Paediatric Oncology·2025· 1 citedOpen Access
Abstract B079: The glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse model
Molecular Cancer Therapeutics·2025
High-throughput 3D engineered paediatric tumour models for precision medicine
Molecular Systems Biology·2025Open Access
Abstract A002-PR011: Precision Diagnosis in High-Risk Pediatric Oncology through Integrated Whole Genome, Transcriptome, and Epigenome Profiling
Cancer Research·2025
<scp>NONO</scp> Maintains <scp>SREBP</scp> ‐Regulated Cholesterol Biosynthesis via <scp>RNA</scp> Binding in Neuroblastoma
The FASEB Journal·2025· 1 citedOpen Access
Arginine depletion potentiates standard-of-care chemo-immunotherapy in preclinical models of high-risk neuroblastoma
Journal of Experimental & Clinical Cancer Research·2025Open Access
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity
2025· 1 citedOpen Access
Figure S1 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
2025Open Access
Figure 5 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
Figshare·2025Open Access
Table S2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
2025Open Access
Figure S4 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
Figshare·2025Open Access
Data from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
2025Open Access
Figure S2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
Figshare·2025Open Access
Figure S3 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
Figshare·2025Open Access
Figure 4 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
2025Open Access
Table S1 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
2025Open Access
Table 1 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
2025Open Access
Figure 3 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy
2025Open Access
page 1 of 13Next →

Frequent Co-authors

Michelle Haber(25), Murray D. Norris(22), Glenn M. Marshall(15), Alvin Kamili(11), Andrew J. Gifford(10), David C.S. Huang(9), Jayne Murray(9), Chelsea Mayoh(9), Toby N. Trahair(9), Michelle J. Henderson(8), Claudia L. Flemming(8), Belamy B. Cheung(7), Glenn F. King(6), Denise Yu(6), Daniel R. Carter(6), Georgina L. Eden(6), David S. Ziegler(6), Tao Liu(6), Simon N. Willis(5), Jerry M. Adams(5)